Merck Announces Psaio Tx as finalist prize winner in their Emerging Biotech Grant Program at Ausbiotech 2024
November 12, 2024
The Myrio team recently participated in the Spring edition of the Society for Immunotherapy of Cancer (SITC), where Matt Beasley (Co-founder, CSO) and Dr. Lauren Pitt (Head of Preclinical) presented at the poster session “Exploiting peptide presentation for the development of novel immunotherapies.”
Why This Matters
KRAS remains one of the most formidable oncogenic drivers in solid tumors. The KRAS oncogene produces cancer specific peptides that present on the surface of the tumor cells in the context of the human leukocyte antigen (HLA) system—part of the way the body signals that tissues come from the self . Cutting-edge advancements in immunopeptidomics are reshaping how we approach this critical target. Myrio’s lead KRAS program leverages this innovative technology to accurately identify and target immunogenic peptides, enhancing T-cell potency and specificity while minimizing off-target effects.
- KRAS mutations drive 30% of solid tumors, making them a top priority for novel therapeutic development.
- Our highly selective peptide-based approach aims to empower T-cells with superior precision and efficacy against KRAS-driven malignancies.
Beyond the poster presentation, Matt and Lauren had the opportunity to engage with Myrio’s global leading research collaborators in cellular therapy, including teams from Stanford University Medicine, University of Pennsylvania Medicine, and New York University School of Medicine (NYU)
Stay tuned for more updates as we continue advancing the next generation of targeted immunotherapies.
